ClinicalTrials.Veeva

Menu

EVOLUTION OF D-DIMER AS A MARKER OF BLEEDING RISK ON ECMO (ECMOstase2)

U

University Hospital, Strasbourg, France

Status

Not yet enrolling

Conditions

ECMO
INTENSIVE CARE
Mplementation of a Veno-venous VV or Veno-arterial VA

Treatments

Other: Blood sampling collection

Study type

Observational

Funder types

Other

Identifiers

NCT07039513
9557 (Other Identifier)
2024-A02754-43 (Other Identifier)

Details and patient eligibility

About

ECMO (extracorporeal membrane oxygenation) is a life-saving device, used in intensive care to treat severe respiratory or cardiac failure. However, it carries a high risk of serious life-threatening bleeding.

Bleeding complications have been attributed to coagulopathy triggered either by the underlying pathology or by the extracorporeal circuit itself, as well as excessive or inappropriate anticoagulation initiated to prevent thrombotic complications.

The objective of this cohort is to confirm the interest of the evolution of D-dimers as a prognostic marker of serious bleeding events in patients on veno-venous (VV) or veno-arterial (VA) ECMO, and to determine the threshold.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female ≥ 18 years of age
  • Hospitalized patient in intensive care
  • Implementation of a VV or VA ECMO for less than 24 hours
  • Patient affiliated to a social protection health insurance scheme
  • Non-opposition by the patient or a relative in the event that the patient is not in a state to express his or her non-opposition or inclusion in an emergency procedure in the event that the patient is not in a state to express his or her non-opposition and no relative of the patient can be reached.

Exclusion criteria

  • Patient on veno-arterial ECMO after cardiac, cardiopulmonary surgery or after placement of a left or biventricular cardiac assist device
  • Congenital hemostasis disorder or anatomical abnormality predisposing to bleeding
  • Dying patient on the day of inclusion
  • Patient under judicial protection
  • Patient under guardianship or curatorship
  • Pregnancy
  • Breastfeeding

Trial contacts and locations

1

Loading...

Central trial contact

Julie HELMS, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems